Table 2 Summary of the mouse TGI data used in this study.
Study | PDX | PARP inhibitor (PARPi) | ATR inhibitor (ATRi) gartisertib | Treatment arms |
|---|---|---|---|---|
1 N = 7 | HBCx-9 | rucaparib 50, 100 mg/kg qd x35 days, BID x35 days | 3 mg/kg qd x35 days 3 mg/kg (1won/1woff)x2 + 1won | 1x PARPi monotherapy 1x ATRi monotherapy 5x combination |
2 N = 7 | HBCx-9 | rucaparib 50 mg/kg qd x28 days | 10, 20 mg/kg once weekly x4 5, 10 mg/kg twice weekly x4 1, 3 mg/kg qd x28 | 1x PARPi monotherapy 2x ATRi monotherapy 6x combination |
3 N = 8 | HBCx-9 | talazoparib 0.15 mg/kg BID x28 days | 10, 20 mg/kg once weekly x4 5, 10 mg/kg twice weekly x4 1, 3 mg/kg qd x28 days 3 mg/kg qd x7 days | 1x PARPi monotherapy 2x ATRi monotherapy 7x combination |
4 N = 9 | HBCx-9 | talazoparib 0.15 mg/kg BID x6 or x8 weeks | 20 mg/kg once weekly x6 20 mg/kg twice weekly x6 (*) 20 mg/kg three times a week x6 (*) (*) Dose reduced to 10 mg/kg from Day 13 | 1x PARPi monotherapy 1x ATRi monotherapy 3x combination |
PDX panel N = 3 | 9 TNBC PDXs (*) | talazoparib 0.3 mg/kg qd x28 | 10, 20 mg/kg twice weekly x4 | 1x PARPi monotherapy 1x ATRi monotherapy 1x combination |
